publication date: Jun. 9, 2017
Issue 23 - Jun. 9, 2017
To access this members-only content, please log in.
If you're not a subscriber why not join today?
If you believe you should be able to view this area but cannot log in, then please contact us and we will try to rectify this issue as soon as possible.
To gain access to the members only content click here to subscribe.
You will be given immediate access to premium content on the site.
Click here to join.
  • How drugs go viral: Flatiron’s real-world data show how uptake happens

    The graphs make it seem so simple:

    Doctors learn about a new therapy. They start to prescribe it. A standard of care is born. In a matter of months.

  • Conversation with The Cancer Letter

    Maria Koehler: Real-world data is “truly a revolution”

    Real-world evidence is more than just another way of tracking post-market patterns in drug utilization, said Maria Koehler, vice president of oncology strategy, innovation and collaborations at Pfizer Oncology.

    New technology for tracking real-world data may soon change the way pharmaceutical companies approach drug development. By analyzing real-time data, industry can use robust evidence from oncology practices to update drug labels, track market trends, and adjust production.

  • Francis Collins to stay on as NIH director in Trump administration

    Donald Trump has asked Francis Collins to remain in his job as NIH director.

    The move means that, as an official of the Trump administration, Collins will have to at least make an appearance of supporting its FY 2018 budget proposal, which would slash NIH by 21 percent and cut indirect costs charged by institutions that house NIH-funded researchers (The Cancer Letter, May 26).

  • Conversation with The Cancer Letter

    Michael Birrer named director of the University of Alabama at Birmingham Comprehensive Cancer Center

    Michael Birrer, an expert in early detection and treatment of gynecologic cancers, was named director of the University of Alabama at Birmingham Comprehensive Cancer Center.

    Birrer, whose job at UAB starts Aug. 1, is director of Medical Gynecologic Oncology and director of the Gynecologic Cancer Research Program at the Massachusetts General Hospital Gillette Cancer Center. Also, he serves as the leader of the Dana Farber/Harvard Cancer Center program in gynecologic cancers and is a professor of medicine at Harvard Medical School.

  • Obituary

    Angela Hartley Brodie, pioneer in the development of breast cancer treatment, dies at 82

    Angela Hartley Brodie, professor emeritus in the Department of Pharmacology at the University of Maryland School of Medicine and a scientist whose groundbreaking research is considered among the greatest advances in treating breast cancer, died of complications from Parkinson’s disease at her home in Fulton, MD. She was 82.

    Brodie pioneered the development of aromatase inhibitor. Her work developing aromatase inhibitors was a paradigm-shifting effort that began in the 1970s and was designed to reduce the level of the estrogen in the body and thereby block the growth of cancer cells.

  • Aggressive marketing transforms tobacco use into social justice issue, report states

    Tobacco use should be addressed as a social justice issue, according to a recent report by Action on Smoking and Health.

    “Aggressive industry marketing targeted at African-Americans, Native American, and the LGBTQI community and others has resulted in a disproportionate level of the overall tobacco burden being borne by those who can financially least endure it,” states a report released for World No Tobacco Day on May 31.

  • In Brief

    • Ben Melson rejoins MD Anderson as chief financial officer
    • Jeffrey Molter named director of communications at NYU Perlmutter Cancer Center
    • ACCC delivers immunotherapy education in community setting
    • Andy North & Friends raise $1.05 million for UW Carbone Cancer Center
  • Drugs and Targets

    • BMS, Novartis announce collaboration focused on metastatic colorectal cancer
    • Roche announces FDA approval of companion diagnostic to identify ALK-positive non-small cell lung cancer patients
    • FDA Approves Hologic’s Genius 3D Mammography Exam
    • Amgen and Allergan announce FDA advisory committee meeting to review ADP 215, a biosimilar candidate to Bevacizumab
    • Hitachi and MD Anderson to collaborate in research in oropharyngeal cancer
  • Funding Opportunities

    • DOD publishes research opportunities in prostate cancer

Copyright (c) 2017 The Cancer Letter Inc.